Epizyme (EPZM) Reports Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial
Tweet Send to a Friend
Epizyme, Inc. (NASDAQ: EPZM) today announced that the National Cancer Institute (NCI), part of the National Institutes of Health, has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
